Item 8.01 Other Events.



As previously reported, Xeris Biopharma Holdings, Inc. ("Xeris" or the
"Company") completed its acquisition (the "Acquisition") of Strongbridge
Biopharma plc, an Irish public limited company ("Strongbridge") on October 5,
2021 (the "Acquisition Closing Date"). Upon completion of the Acquisition, (a)
the Company acquired Strongbridge by means of a scheme of arrangement (the
"Scheme") under Irish law pursuant to which the Company acquired all of the
outstanding ordinary shares of Strongbridge ("Strongbridge Shares") in exchange
for (i) 0.7840 of a share of the Company's common stock ("Company Shares") and
cash in lieu of fractions of Company Shares in exchange for each Strongbridge
Share held by such Strongbridge shareholders and (ii) one (1) non-tradeable
contingent value right ("CVR"), worth up to a maximum of $1.00 per Strongbridge
Share settleable in cash, additional Company Shares, or a combination of cash
and additional Company Shares, at the Company's sole election and (b) Wells
MergerSub, Inc. merged with and into Xeris Pharmaceuticals, Inc. ("Xeris
Pharma") with Xeris Pharma as the surviving corporation in the merger (the
"Merger," and the Merger together with the Acquisition, the "Transactions").

Upon completion of the Merger, (a) each share of Xeris Pharma common stock was
assumed by the Company and converted into the right to receive one Company Share
and any cash in lieu of fractional entitlements due to a Xeris Pharma
shareholder and (b) each Xeris Pharma option, stock appreciation right,
restricted share award and other Xeris Pharma share based award that was
outstanding was assumed by the Company and converted into an equivalent equity
award of the Company, which award was subject to the same number of shares and
the same terms and conditions as were applicable to the Xeris Pharma award in
respect of which it was issued.

This Current Report on Form 8-K is being filed in order to provide as Exhibit
99.1 hereto the unaudited consolidated financial statements of Strongbridge for
the nine months ended September 30, 2021, and as Exhibit 99.2 hereto the
unaudited pro
forma condensed consolidated financial information of Xeris Pharma and
Strongbridge for the nine months ended September 30, 2021. The pro forma
condensed consolidated financial information included herein has been presented
for informational purposes only and is not necessarily indicative of the
combined financial position or results of operations that would have been
realized had the Transactions occurred as of the dates indicated, nor is it
meant to be indicative of any anticipated combined financial position or future
results of operations that Xeris may experience after the Transactions.

The purpose of this Current Report on Form 8-K is to, among other things, file
the financial statements of Strongbridge and pro forma condensed consolidated
financial information discussed above, and to allow such financial information
to be incorporated by reference into Xeris's registration statements filed with
the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.



(a) Financial Statements of Business Acquired.
The unaudited consolidated financial statements of Strongbridge as of September
30, 2021 and for the nine months ended September 30, 2021, together with the
related notes to the financial statements, are filed as Exhibit 99.1 to this
Current Report on Form 8-K and are incorporated herein by reference.

(b) Pro forma financial information.
The following unaudited pro forma condensed combined financial information of
the Company, giving effect to the Transactions as if it had been completed on
January 1, 2020, is included in Exhibit 99.2 hereto:

•Unaudited Pro Forma Condensed Balance Sheet as of September 30, 2021
•Unaudited Pro Forma Condensed Combined Statement of Operations for the year
ended December 31, 2020
•Unaudited Pro Forma Condensed Combined Statement of Operations for the nine
months ended September 30, 2021
•Notes to the unaudited Pro Forma Condensed Combined Financial Information

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:

--------------------------------------------------------------------------------



Exhibit Number                   Description
                                   Unaudited     consolidated financial statement of Strongbridge
99.1                               Biopharma plc     for the nine months ended September 3    0    , 2021
                                   Unaudited     p    ro     f    orma     c    ondensed     c    ombined
                                     f    inancial     i    nformation     of Xeris Biopharm    a
99.2                               Holding    s, Inc.
                                 Cover Page Interactive Data File (embedded within the Inline XBRL
104                              document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses